Merck, Inc.

CytomX Therapeutics announced initial Phase 1 biomarker data for CX-801, a masked interferon alpha-2b PROBODY cytokine, demonstrating tumor-selective interferon signaling activation in advanced melanoma patients.

Formycon AG successfully completed patient enrollment for its Dahlia pharmacokinetic study with 96 participants, comparing biosimilar candidate FYB206 to Keytruda in melanoma patients.

BioInvent successfully developed a population model to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad dose range, supporting optimal dose selection for upcoming Phase 2a studies.

DelveInsight's 2025 report reveals over 80 companies are actively developing more than 80 pipeline therapies for pancreatic ductal adenocarcinoma treatment.

• DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer. • Several promising candidates are advancing through clinical trials, including GlycoMimetics' uproleselan in Phase III, BioSight's aspacytarabine (BST-236) in Phase II, and novel approaches like Senti Biosciences' logic-gated CAR-NK cell therapy. • Recent developments include Moleculin Biotech's Phase III MIRACLE trial for annamycin, Qurient's adrixetinib IND approval, and Rigel Pharmaceuticals' trial of REZLIDHIA in combination therapy for IDH1-mutated AML.

• The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates. • Long-acting injectables (LAIs) are gaining traction despite higher costs, offering an alternative to oral antipsychotics. • The US dominates the schizophrenia market due to a large patient population and high drug costs. • Emerging treatments like Cobenfy, evenamide, Ingrezza, and iclepertin aim to address unmet needs in managing both positive and negative symptoms.

Long-term follow-up of the KEYNOTE-671 trial demonstrates that perioperative pembrolizumab plus chemotherapy continues to improve event-free survival (EFS) and overall survival (OS).

The Phase III LEAP-001 trial evaluated lenvatinib plus pembrolizumab versus chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer.

Lupin secured tentative FDA approval for its generic version of Raltegravir 600mg tablets, a treatment for HIV-1 infection.

A phase II study (OLIE) found that adding lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival (PFS) in pediatric and young adult patients with relapsed osteosarcoma.